| Multiple Myeloma

Elrexfio vs Velcade

Side-by-side clinical, coverage, and cost comparison for multiple myeloma.

Deep comparison between: Elrexfio vs Velcade with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsVelcade has a higher rate of injection site reactions vs Elrexfio based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Velcade but not Elrexfio, including UnitedHealthcare

Category

Elrexfio

Velcade

At A Glance

RouteSC injection

FrequencyWeekly to every 4 weeks

ClassBCMA-directed T-cell engager

RouteSC or IV injection

FrequencyTwice weekly

ClassProteasome inhibitor

Indications

Multiple Myeloma

Multiple Myeloma
Carcinoma in situ of other and unspecified small intestine NOS

Dosing

Multiple Myeloma Step-up SC dosing: 12 mg on Day 1, 32 mg on Day 4, then 76 mg weekly starting Day 8 through week 24; for responders, transitions to 76 mg every 2 weeks (weeks 25-48), then 76 mg every 4 weeks (week 49 onward); continue until disease progression or unacceptable toxicity.

Multiple Myeloma 1.3 mg/m2 SC or IV; previously untreated: twice weekly (Days 1, 4, 8, 11) in cycles 1-4 then once weekly (Days 1, 8, 22, 29) in cycles 5-9 with melphalan and prednisone for 9 six-week cycles; relapsed: twice weekly (Days 1, 4, 8, 11) every 3 weeks as single agent or with dexamethasone.

Carcinoma in situ of other and unspecified small intestine NOS 1.3 mg/m2 IV twice weekly (Days 1, 4, 8, 11) for 2 weeks followed by a 10-day rest period, in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (VcR-CAP) for 6 three-week cycles.

Contraindications

—

Hypersensitivity (not including local reactions) to bortezomib, boron, or mannitol, including anaphylactic reactions
Intrathecal administration

Drug Interactions

26View drug interactions

1286View drug interactions

Adverse Reactions

Most common (>=20%) CRS, fatigue, injection site reaction, diarrhea, upper respiratory tract infection, musculoskeletal pain, pneumonia, decreased appetite, rash, cough, nausea, pyrexia

Serious Pneumonia, sepsis, CRS, upper respiratory tract infection, acute kidney injury, urinary tract infection, COVID-19, encephalopathy, pyrexia, febrile neutropenia

Most common (>=10%) Nausea, diarrhea, fatigue, peripheral neuropathies, thrombocytopenia, vomiting, constipation, pyrexia, anorexia, anemia, headache, neutropenia, rash, paresthesia, dizziness, weakness

Serious Diarrhea, vomiting, pyrexia, nausea, dehydration, thrombocytopenia, pneumonia, dyspnea, peripheral neuropathies, herpes zoster

Postmarketing Cardiac tamponade, bilateral deafness, optic neuropathy, blindness, ischemic colitis, progressive multifocal leukoencephalopathy, herpes meningoencephalitis, posterior reversible encephalopathy syndrome, Guillain-Barre syndrome, demyelinating polyneuropathy, acute diffuse infiltrative pulmonary disease, Stevens-Johnson syndrome/toxic epidermal necrolysis, acute febrile neutrophilic dermatosis

Pharmacology

Elranatamab-bcmm is a bispecific BCMA-directed CD3 T-cell engaging antibody that simultaneously binds BCMA on plasma cells, plasmablasts, and multiple myeloma cells and CD3 on T-cells, leading to T-cell activation and cytolysis of BCMA-expressing cells.

Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells; inhibition of this pathway disrupts homeostatic proteolysis, affecting multiple signaling cascades and leading to cell death in various cancer cell types including multiple myeloma.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Elrexfio